Fmr LLC Sells 120,776 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Fmr LLC trimmed its position in shares of Replimune Group, Inc. (NASDAQ:REPL) by 16.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 626,412 shares of the company’s stock after selling 120,776 shares during the quarter. Fmr LLC owned approximately 0.92% of Replimune Group worth $6,865,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in REPL. Quest Partners LLC boosted its position in shares of Replimune Group by 30.4% during the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after buying an additional 3,150 shares during the last quarter. Algert Global LLC increased its stake in Replimune Group by 5.4% in the 2nd quarter. Algert Global LLC now owns 84,033 shares of the company’s stock worth $756,000 after buying an additional 4,340 shares in the last quarter. Creative Planning boosted its stake in Replimune Group by 28.7% in the 3rd quarter. Creative Planning now owns 21,047 shares of the company’s stock worth $231,000 after purchasing an additional 4,699 shares during the period. Nisa Investment Advisors LLC increased its holdings in Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after acquiring an additional 4,946 shares during the last quarter. Finally, Los Angeles Capital Management LLC boosted its stake in Replimune Group by 8.1% during the second quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock valued at $646,000 after buying an additional 5,410 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on REPL shares. Jefferies Financial Group upped their price objective on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Roth Mkm started coverage on Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $17.00 price objective on shares of Replimune Group in a report on Friday, November 22nd. Finally, BMO Capital Markets upped their target price on Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a research note on Friday, November 22nd. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $17.29.

Replimune Group Trading Down 3.3 %

Shares of REPL stock opened at $12.22 on Friday. The stock’s fifty day moving average is $12.17 and its two-hundred day moving average is $10.40. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The firm has a market capitalization of $836.06 million, a P/E ratio of -4.01 and a beta of 1.26. Replimune Group, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $17.00.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. Research analysts expect that Replimune Group, Inc. will post -2.91 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the sale, the insider now owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.80% of the stock is currently owned by insiders.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.